RACHEL SCHIFF to Female
This is a "connection" page, showing publications RACHEL SCHIFF has written about Female.
Connection Strength
0.971
-
HER2-Positive Breast Cancer Treatment and Resistance. Adv Exp Med Biol. 2025; 1464:495-525.
Score: 0.038
-
Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic. Endocrinology. 2022 01 01; 163(1).
Score: 0.031
-
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882.
Score: 0.029
-
Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020 04; 17(4):233-250.
Score: 0.027
-
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745.
Score: 0.027
-
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
Score: 0.025
-
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
Score: 0.023
-
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.
Score: 0.023
-
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer. Curr Oncol Rep. 2017 May; 19(5):35.
Score: 0.023
-
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
Score: 0.022
-
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
Score: 0.021
-
ESR1 mutations?a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015 Oct; 12(10):573-83.
Score: 0.020
-
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
Score: 0.019
-
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat. 2014 Apr; 144(2):263-72.
Score: 0.018
-
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast. 2013 Aug; 22 Suppl 2:S12-8.
Score: 0.017
-
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2):583-93.
Score: 0.016
-
Die and let live: harnessing BikDD to combat breast cancer stem cells. Breast Cancer Res. 2012 May 23; 14(3):310.
Score: 0.016
-
More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response. Breast Cancer Res. 2011 Apr 20; 13(2):307.
Score: 0.015
-
Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62:233-47.
Score: 0.015
-
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.
Score: 0.014
-
Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
Score: 0.012
-
The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clin Cancer Res. 2007 Dec 01; 13(23):6921-5.
Score: 0.012
-
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007 May 02; 99(9):694-705.
Score: 0.011
-
Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 2007 Apr 01; 13(7):1950-4.
Score: 0.011
-
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.
Score: 0.011
-
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005 Nov; 56 Suppl 1:10-20.
Score: 0.010
-
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res. 2005; 7(5):205-11.
Score: 0.010
-
Aromatase inhibitors: future directions. J Steroid Biochem Mol Biol. 2005 May; 95(1-5):183-7.
Score: 0.010
-
Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005 Mar 10; 23(8):1616-22.
Score: 0.010
-
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):865s-70s.
Score: 0.010
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
Score: 0.009
-
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004 Jun 16; 96(12):926-35.
Score: 0.009
-
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer. Clin Cancer Res. 2024 May 01; 30(9):1889-1905.
Score: 0.009
-
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003 Dec; 12(6):362-7.
Score: 0.009
-
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
Score: 0.009
-
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
Score: 0.008
-
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):447S-54S.
Score: 0.008
-
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. Cancer Res. 2022 10 17; 82(20):3673-3686.
Score: 0.008
-
Elacestrant and the Promise of Oral SERDs. J Clin Oncol. 2022 10 01; 40(28):3227-3229.
Score: 0.008
-
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Sci Rep. 2022 02 04; 12(1):1972.
Score: 0.008
-
Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. Breast Cancer Res Treat. 2021 Nov; 190(2):189-201.
Score: 0.008
-
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer. FASEB J. 2021 07; 35(7):e21719.
Score: 0.008
-
The bone microenvironment increases phenotypic plasticity of ER+ breast cancer cells. Dev Cell. 2021 04 19; 56(8):1100-1117.e9.
Score: 0.007
-
Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 05 01; 27(9):2648-2662.
Score: 0.007
-
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
Score: 0.007
-
The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells. Biochim Biophys Acta Gene Regul Mech. 2020 11; 1863(11):194631.
Score: 0.007
-
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Res. 2020 08 08; 22(1):84.
Score: 0.007
-
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance. Nat Cell Biol. 2020 06; 22(6):701-715.
Score: 0.007
-
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2020 Mar; 84:101965.
Score: 0.007
-
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.
Score: 0.007
-
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
Score: 0.007
-
In vivo longitudinal imaging of RNA interference-induced endocrine therapy resistance in breast cancer. J Biophotonics. 2020 01; 13(1):e201900180.
Score: 0.007
-
The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20528-20538.
Score: 0.007
-
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Mol Cancer Res. 2019 11; 17(11):2318-2330.
Score: 0.007
-
Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance. Nat Commun. 2019 04 03; 10(1):1522.
Score: 0.006
-
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer. 2019 Mar 12; 19(1):220.
Score: 0.006
-
AhR ligand aminoflavone suppresses a6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells. J Cell Physiol. 2018 01; 234(1):108-121.
Score: 0.006
-
Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. Mol Cancer Ther. 2018 05; 17(5):921-930.
Score: 0.006
-
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
Score: 0.006
-
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):279-292.
Score: 0.006
-
Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERa-GREB1 Transcriptional Axis. Cancer Res. 2018 02 01; 78(3):671-684.
Score: 0.006
-
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast. 2017 Aug; 34 Suppl 1:S19-S26.
Score: 0.006
-
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proc Natl Acad Sci U S A. 2017 05 30; 114(22):E4482-E4491.
Score: 0.006
-
Identification of MYST3 as a novel epigenetic activator of ERa frequently amplified in breast cancer. Oncogene. 2017 05 18; 36(20):2910-2918.
Score: 0.005
-
Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nat Commun. 2016 10 03; 7:12991.
Score: 0.005
-
Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint. Mol Cancer Res. 2016 10; 14(10):920-927.
Score: 0.005
-
The changing role of ER in endocrine resistance. Breast. 2015 Nov; 24 Suppl 2:S60-6.
Score: 0.005
-
Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. Clin Breast Cancer. 2015 Dec; 15(6):448-457.e2.
Score: 0.005
-
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
Score: 0.005
-
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
Score: 0.005
-
Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28.
Score: 0.005
-
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle. 2015; 14(4):648-55.
Score: 0.005
-
Photo activation of HPPH encapsulated in "Pocket" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts. Int J Nanomedicine. 2015; 10:125-45.
Score: 0.005
-
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32.
Score: 0.005
-
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577.
Score: 0.005
-
Sub-100nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors. J Control Release. 2014 Oct 10; 191:90-97.
Score: 0.005
-
Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshells. ACS Nano. 2014 Jun 24; 8(6):6372-81.
Score: 0.005
-
An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
Score: 0.005
-
Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia. 2014 May; 16(5):390-402.
Score: 0.005
-
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med. 2014 Mar 26; 6(229):229ra41.
Score: 0.005
-
Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol. 2014 Jan; 232(1):75-86.
Score: 0.004
-
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014 Jan; 124(1):398-412.
Score: 0.004
-
Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013 Dec 01; 19(23):6389-97.
Score: 0.004
-
PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. Cancer Cell. 2013 Jun 10; 23(6):753-67.
Score: 0.004
-
Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer. Pharmacotherapy. 2013 Oct; 33(10):1126-9.
Score: 0.004
-
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97.
Score: 0.004
-
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
Score: 0.004
-
SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(2):531-41.
Score: 0.004
-
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53.
Score: 0.004
-
Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res. 2012 Jan 01; 18(1):118-26.
Score: 0.004
-
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011 Mar 04; 144(5):703-18.
Score: 0.004
-
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3665-70.
Score: 0.004
-
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011 Mar 01; 17(5):1147-59.
Score: 0.004
-
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011 Jan 10; 29(2):166-73.
Score: 0.004
-
Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo. Nano Lett. 2010 Dec 08; 10(12):4920-8.
Score: 0.004
-
Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Neoplasia. 2010 Sep; 12(9):718-26.
Score: 0.004
-
Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res Treat. 2011 Jan; 125(1):27-34.
Score: 0.003
-
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer. 2010 Mar 01; 116(5):1234-42.
Score: 0.003
-
Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res. 2009 Jul 15; 15(14):4712-21.
Score: 0.003
-
Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat. 2009 Sep; 117(2):243-51.
Score: 0.003
-
Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med. 2007 Sep; 48(9):1501-10.
Score: 0.003
-
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006 Aug; 98(3):315-27.
Score: 0.003
-
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005 Oct 20; 23(30):7721-35.
Score: 0.003
-
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005 Dec; 14(6):458-65.
Score: 0.003
-
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005 Sep 07; 97(17):1254-61.
Score: 0.003
-
Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene. 2005 Apr 28; 24(19):3166-76.
Score: 0.002
-
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005 Apr 10; 23(11):2469-76.
Score: 0.002
-
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
Score: 0.002
-
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol. 2003 Aug; 17(8):1543-54.
Score: 0.002
-
New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):516S-23S.
Score: 0.002
-
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.
Score: 0.002
-
Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s.
Score: 0.002